| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : DRUG INTERACTIONSolvent/Active Compound : aqueous extractType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : -Duration : -Type of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : PositiveRemark : P. emblica aqueous extract demonstrated inhibitory effects on CYP1A2, CYP2C9, CYP2D6, CYP2E1 and CYP3A4 with IC50 of 310.27 +/- 5.07, 194.72 +/- 2.94, 589.52 +/- 14.32, 310.27 +/- 15.06 and 325.54 +/- 7.44 micrograms/mL, respectively.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg clopidogrelDuration : -Type of interaction : PharmacodynamicsInteraction with drug : ClopidogrelDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + clopidogrel was 49.78%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg clopidogrelDuration : -Type of interaction : PharmacodynamicsInteraction with drug : ClopidogrelDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + clopidogrel was 49.78%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg ecosprinDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : single dose of 500 mg Phyllanthus emblica extract + 75 mg ecosprinDuration : -Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to baseline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg clopidogrel once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : ClopidogrelDose/Conc.(drug) : -Result : PositiveRemark : Result: Ten days treatment produced significant decrease of platelet aggregation compared to baseline. The mean percent inhibition of platelet aggregation on multiple dose administration dose administration with combination P. emblica + clopidogrel 75 mg was 53.42%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + clopidogrel Vs clopidogrel alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg clopidogrel once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : ClopidogrelDose/Conc.(drug) : -Result : PositiveRemark : Result: Ten days treatment produced significant decrease of platelet aggregation compared to baseline. The mean percent inhibition of platelet aggregation on multiple dose administration dose administration with combination P. emblica + clopidogrel 75 mg was 53.42%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + clopidogrel Vs clopidogrel alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg ecosprin once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to basline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%. The mean percent inhibition of platelet aggregation on multiple dose administration with combination P. emblica + ecosprin 75 mg was 56.65%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + ecosprin Vs. ecosprin alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : Phyllanthus emblica extractType of experiment : humanType of animal : -Type of study : Cross overN(Total) : 10* (M/F = 6/4)N(Treatment) : 10 (M/F = 6/4)Sex : Both sexAge : 58.60+/-10.54 yrs.Route : Oral administrationDose/Conc.(herb) : 500 mg P. emblica extract twice daily + 75 mg ecosprin once dailyDuration : 10 days.Type of interaction : PharmacodynamicsInteraction with drug : Aspirin*/Acetylsalicylic acid/ASA/EcosprinDose/Conc.(drug) : -Result : PositiveRemark : Result: Combination therapy produced a significant decrease of platelet aggregation after 4 h of treatment, compared to basline. The percentage inhibition with the combination of P. emblica + ecosprin was 49.25%. The mean percent inhibition of platelet aggregation on multiple dose administration with combination P. emblica + ecosprin 75 mg was 56.65%. There was statistically significant change observed when combination treatments were compared to P. emblica alone. Though there was apparent increase in inhibition of platelet aggregation with P. emblica + ecosprin Vs. ecosprin alone, this difference was not however statistically significant.Note : *Subject total: Subjects were type II diabetic patients. Conclusion: P. emblica extract demonstrated significant antiplatelet activity with both single and multiple dose administration.
Part Used : ผลActivity : DRUG INTERACTIONSolvent/Active Compound : waterType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : Combination assays were performed using appropriate concentrations of P. emblica and T. bellerica extracts (4, 8, 16, 24 and 48 micrograms/mL for A549 cells, and 25, 50, 75, 100, and 200 micrograms/mL for HepG2 cells) with appropriate concentrations of doxorubicin (0.029, 0.058, 0.116, 0.174, and 0.348 micrograms/mL) or cisplatin (0.1, 0.2, 0.3, 0.4, and 0.8 micrograms/mL).Duration : -Type of interaction : PharmacodynamicsInteraction with drug : Doxorubicin*/Adrimycin/ADR/AdriaDose/Conc.(drug) : -Result : PositiveRemark : - With A549 cells, the combinations were synergistic at medium and high dose levels (IC75 and IC90) for the P. emblica/doxorubicin and P. emblica/cisplatin combinations. By contrast, the synergistic and additive effects were recorded at low and medium dose levels (IC50 and IC75) for the T. bellerica/cisplatin combination. In HepG2 cells, combinations were synergistic at low and medium dose levels (IC50 and IC75) for the P. emblica/doxorubicin combination or at a low level (IC50) for the T. bellerica/doxorubicin combination. All other combinations had antagonistic effects. - The growth inhibitory activity of doxorubicin or cisplatin, as a single agent, may be modified by combinations of P. emblica or T. bellerica extracts and be synergistically enhanced in some cases. Depending on the combination ratio, the doses for each drug for a given degree of effect in the combination may be reduced.
